Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 10:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 741 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Headache, Migraine Clear all
Withdrawn No phase listed Observational

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Migraine Headaches

NCT04211454
View directory record Official record
Conditions
Migraine
Interventions
No intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 22, 2026, 10:22 AM EDT
Completed Phase 3 Interventional

A Phase III Open-Label, Multi-Center, Long-Term Extension Study of Depakote ER in Subjects Who Either Completed or Prematurely Discontinued Due to Ineffectiveness From Study M02-488.

NCT00195754
View directory record Official record
Conditions
Migraines
Interventions
divalproex sodium
Drug
Lead sponsor
Abbott
Industry
Eligibility
12 Years to 17 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2007 · Synced Sep 22, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Results available

Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine

NCT01300546
View directory record Official record
Conditions
Migraine
Interventions
Sumatriptan/Naproxen Sodium, Naproxen Sodium
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Newport Beach, California • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Sep 22, 2026, 10:22 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

NCT03432286
View directory record Official record
Conditions
Episodic Migraine
Interventions
Galcanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
38
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 22, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden

NCT04461795
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]
Drug
Lead sponsor
David True
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
City of Saint Peters, Missouri • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Sep 22, 2026, 10:22 AM EDT
Withdrawn Phase 4 Interventional

Prochlorperazine Versus Prochlorperazine & Ketorolac in Treatment of Pediatric Migraine in the Emergency Department

NCT01534806
View directory record Official record
Conditions
Migraine
Interventions
Ketorolac, Placebo
Drug
Lead sponsor
Akron Children's Hospital
Other
Eligibility
8 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2014 · Synced Sep 22, 2026, 10:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects

NCT01507610
View directory record Official record
Conditions
Migraine
Interventions
Sumatriptan
Drug
Lead sponsor
Optinose US Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Sep 22, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Study in the Pediatric Pain Population

NCT03055767
View directory record Official record
Conditions
Migraine Disorders, Headache, Migraine, Pediatrics
Interventions
OnabotulinumtoxinA, Placebo (Saline)
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
8 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Irvine, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Sep 22, 2026, 10:22 AM EDT
Recruiting Not applicable Interventional

A Feasibility Trial of Virtual Reality Neurofeedback for Adolescents With Migraine

NCT07454798
View directory record Official record
Conditions
Migraine, Headache Disorders, Primary
Interventions
Immersive Neurofeedback Self-Regulation Training (INSeRT), Virtual Reality Imagery (No Neurofeedback)
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
10 Years to 16 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 22, 2026, 10:22 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

NCT04396236
View directory record Official record
Conditions
Migraine
Interventions
Lasmiditan, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
77
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 22, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

A Multicenter Assessment of ALD403 in Frequent Episodic Migraine

NCT02559895
View directory record Official record
Conditions
Migraine Disorders
Interventions
ALD403, Placebo
Drug
Lead sponsor
Alder Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
898 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
83
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Sep 22, 2026, 10:22 AM EDT
Completed Not applicable Interventional Results available

Prospective, Multi-Center Evaluation of the Efficacy of Peripheral Trigger Decompression Surgery for Migraine Headaches

NCT02351544
View directory record Official record
Conditions
Migraine Headaches
Interventions
Botulinum Toxin Type A, Surgery, Daily headache diary, Migraine Disability Assessment Test (MIDAS), Migraine Work and Productivity Loss Questionnaire (MWPLQ), Migraine-Specific Quality of Life Questionnaire (MSQ)
Drug · Procedure · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
6
States / cities
San Francisco, California • Olathe, Kansas • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2024 · Synced Sep 22, 2026, 10:22 AM EDT
Completed Not applicable Interventional Results available

Acute Treatment of Migraine With e-TNS

NCT02590939
View directory record Official record
Conditions
Migraine
Interventions
CEFALY Active, CEFALY Placebo
Device
Lead sponsor
Cefaly Technology
Industry
Eligibility
18 Years to 65 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
New Haven, Connecticut • Lenexa, Kansas • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 22, 2026, 10:22 AM EDT
Terminated Phase 4 Interventional Results available

Prochlorperazine Versus Acetaminophen, Aspirin, and Caffeine for the Treatment of Acute Migraine

NCT01629329
View directory record Official record
Conditions
Migraine Headaches
Interventions
Aspirin, Acetaminophen, Caffeine pills, Prochlorperazine 10mg
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Sep 22, 2026, 10:22 AM EDT
Completed No phase listed Observational Results available

A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.

NCT06532357
View directory record Official record
Conditions
Migraine
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 22, 2026, 10:22 AM EDT
Terminated Not applicable Interventional

Feasibility of Using a Mobile Device Controlled Micro-pressure Pulse Insufflator for Acute Migraine Relief

NCT03263897
View directory record Official record
Conditions
Migraine
Interventions
insufflation, placebo insufflation
Device
Lead sponsor
Caps Research Network
Other
Eligibility
20 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Prescott, Arizona • Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 22, 2026, 10:22 AM EDT
Completed Not applicable Interventional Results available

Cranial Electrotherapy Stimulation in the Treatment of Migraine Headaches

NCT01265797
View directory record Official record
Conditions
Migraine
Interventions
Cranial Electrostimulator, Sham Device
Device
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 9, 2015 · Synced Sep 22, 2026, 10:22 AM EDT
Completed Not applicable Interventional

Migraine--Investigational Treatment of Migraine With Noninvasive Brain Stimulation. (tDCS- Migraine)

NCT00521196
View directory record Official record
Conditions
Migraine
Interventions
DC Stimulator (Transcranial Direct Current Stimulator)
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 22, 2026, 10:22 AM EDT
Completed Not applicable Interventional

RELAXaHEAD for Headache Patients (Phase I)

NCT03183791
View directory record Official record
Conditions
Headache, Migraine, Multiple Sclerosis
Interventions
RELAXaHEAD app, Monitored Usual Care (MUC)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2022 · Synced Sep 22, 2026, 10:22 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Study of Low-dose Naltrexone in Chronic Migraine With Fibromyalgia

NCT05536050
View directory record Official record
Conditions
Chronic Migraine, Fibromyalgia, New Daily Persistent Headache
Interventions
Migraine diary and Questionnaires
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Sep 22, 2026, 10:22 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA

NCT05754190
View directory record Official record
Conditions
Chronic Pain, Acute Pain, Post Operative Pain, Fibromyalgia, Primary, Fibromyalgia, Secondary, Fibromyalgia, Irritable Bowel Syndrome, Chronic Headache Disorder, Chronic Migraine, Chronic Pelvic Pain Syndrome, Temporomandibular Joint Disorders, Endometriosis-related Pain, Arthritis, Chronic Low-back Pain, Failed Back Surgery Syndrome, Post Herpetic Neuralgia, Neuropathic Pain, Painful Diabetic Neuropathy, Painful Bladder Syndrome, Trauma-related Wound, Trauma, Multiple, Chronic Pain Syndrome, Chronic Shoulder Pain
Interventions
SOMA pain manager smartphone application
Device
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 22, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine

NCT00846495
View directory record Official record
Conditions
Migraine
Interventions
topiramate, frovatriptan
Drug
Lead sponsor
Clinvest
Individual
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Oviedo, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Sep 22, 2026, 10:22 AM EDT
Terminated Not applicable Interventional Results available

Spectacle Tints and Thin-Films for Migraine

NCT02720211
View directory record Official record
Conditions
Headache Migraine Chronic
Interventions
Gray tinted spectacle lenses, Thin-Film spectacle lenses
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Phoenix, Arizona • Boston, Massachusetts • Great Neck, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Sep 22, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of E2007 in Migraine Prophylaxis

NCT00154063
View directory record Official record
Conditions
Migraine Prophylaxis
Interventions
E2007, Placebo
Drug · Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
9
States / cities
Oceanside, California • Santa Monica, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 22, 2026, 10:22 AM EDT